申请人:Takeda Chemical Industries, Ltd.
公开号:EP0202589A2
公开(公告)日:1986-11-26
wherein R1 is organic residue having molecular weight of from 15 to 700, R2 is hydrogen or hydroxyl, R3 is hydrogen, acyl, optionally substituted phosphono or sulfo, and R3 and hydroxyl of R2 may form acetal residue or ketal residue, and a salt thereof are provided.
The compound (I) and salts thereof have excellent prophylactic and improving actions on disorders of circulatory functions, and they are useful as agents of prophylaxis and improvement of circulatory functional disorders.
其中 R1 是分子量为 15 至 700 的有机残基,R2 是氢或羟基,R3 是氢、酰基、任选取代的膦酰基或磺酰基,R3 和 R2 的羟基可形成缩醛残基或酮缩残基。
化合物(I)及其盐对循环功能紊乱有很好的预防和改善作用,可作为预防和改善循环功能紊乱的药物。